GSK plc (GSK) ADR Each Repr 2 Ord Shares GBP0.25

Sell:$56.28Buy:$56.29Price increased$1.10 (1.98%)

Prices delayed by at least 15 minutes

Sell:$56.28
Buy:$56.29
Change:Price increased$1.10 (1.98%)
Prices delayed by at least 15 minutes

Sell:$56.28
Buy:$56.29
Change:Price increased$1.10 (1.98%)
Prices delayed by at least 15 minutes

Company Information

About this company

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. General medicines include inhaled medicines for asthma and COPD with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. It is in phase IIb clinical development for prophylactic protection against food allergens.

Key people

Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Phil C. Thomson
President - Global Affairs
Deborah Waterhouse
Chief Executive Officer - ViiV Healthcare and President - GSK Global Health
Hal V. Barron
Non-Executive Director
Elizabeth McKee Anderson
Independent Non-Executive Director
Luke Miels
Chief Executive Officer, Executive Director
Charles A. Bancroft
Senior Independent Non-Executive Director
Anne Beal
Independent Non-Executive Director
Julie Brown
Chief Financial Officer, Executive Director
Lynn Baxter
President, Europe
Mike Crichton
President, International
Maya Martinez-Davis
President, US
Nina Mojas
President - Global Product Strategy
David S. Redfern
President - Corporate Development
Regis Simard
President - Global Supply Chain
Click to see more

Key facts

  • Shares in issue
    4.32bn
  • EPIC
    GSK
  • ISIN
    US37733W2044
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $111.05bn
  • Employees
    66,841
  • Exchange
    New York Stock Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.